J&J Unit Fights Teva's Bid To Revoke Its Prostate IP
By Bonnie Eslinger (September 6, 2021, 9:13 AM BST) -- A subsidiary of Johnson & Johnson has fought back against a lawsuit brought by Teva Pharmaceuticals, rejecting claims by the generic drugmaker that the patent for its prostate cancer drug is invalid.
Janssen Oncology Inc. has denied the Israeli firm's assertion that its patent's priority application has "no clear and unambiguous disclosure" for a method of treating prostate cancer involving the hormone therapy abiraterone acetate in combination with prednisone, a corticosteroid.
Janssen hit back in its Aug. 31 filing in defense to Teva's claim at the High Court.
The subsidiary added that the "skilled addressee" — an individual working in the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!